About me
Stacey Rivkin is the Senior Vice President of Commercial Strategy at H1, where she ensures that what H1 builds delivers real value to clients—and that the commercial team can clearly articulate that value. Sitting at the intersection of product, data, and commercial strategy, she listens to customers and drives alignment across teams to bring innovative offerings to market. With nearly 20 years in the pharmaceutical industry, Stacey is a recognized leader in stakeholder engagement, medical strategy, and commercialization. Before joining H1, she played a pivotal role in shaping global expert identification and engagement strategies at Allergan and Boehringer Ingelheim, helping medical affairs and commercial teams navigate complex landscapes and build meaningful relationships with external experts. Her pharmaceutical journey began at Merck, where she worked in both field sales and medical affairs, gaining deep expertise across multiple therapeutic areas. She’s been involved in every stage of the pharmaceutical lifecycle, from early development to blockbuster commercialization. One of her proudest career moments was being part of the Boehringer team that drove the FDA approval of Jardiance® (empagliflozin) in 2016—the first diabetes medication proven to reduce cardiovascular death in adults with type 2 diabetes. Before pharma, Stacey cut her teeth in high-stakes market research and political strategy at Penn, Schoen & Berland, where she advised corporate giants like Microsoft and SlimFast, as well as political heavyweights including Bill Clinton, Jon Corzine, and Michael Bloomberg. A Cornell University graduate with a BA in Government, Stacey thrives at the intersection of data, strategy, and storytelling. She lives outside New York City with her husband, three kids, and their pandemic puppy, Otis.
